Neoadjuvant immunotherapy improves outcomes in high-risk melanoma patients.

Published Date: 02 Mar 2023

High-risk melanoma patients who received the drug pembrolizumab before or after surgery to remove the cancer had a higher risk of developing melanoma than those who did not have a similar condition that eliminated cancer cells.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Psychotropics Linked to Increased BMI, CVD Risk

2.

Enhancing Comprehensive Biomarker Testing and Biomarker-Directed Treatment Selection

3.

Scientists are investigating the prevention of recurrent breast cancer, which frequently results in death.

4.

Maintenance Rituximab Improves Survival in Elderly MRD-Negative MCL Patients.

5.

Providing essential cancer care to rural communities


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot